Acadia Pharmaceuticals Inc.

ACADNASDAQ • USD
19.16 USD
↗ 0.41 (2.16%)🟢LIVE (AS OF 10:32 AM EST)
🟢Market: OPEN

Shares of Acadia Pharmaceuticals Inc. (ACAD) are trading at $19.16. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (26.1%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place ACAD at a fair price relative to peers.

Technical & fundamental data as of Nov 13, 2026.

Open?$18.84
High?$19.17
Low?$18.33
Prev. Close?$18.75
Volume?276.3K
Avg. Volume?2.4M
VWAP?$18.90
Rel. Volume?0.11x
Bid / Ask
Bid?$19.08 × 200
Ask?$19.76 × 100
Spread?$0.68
Midpoint?$19.42
Valuation & Ratios
Market Cap?3.2B
Shares Out?172.8M
Float?127.6M
Float %?74.1%
P/E Ratio?8.95
P/B Ratio?2.34
EPS?$2.10
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Employees
798
Market Cap
3.2B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2004-05-27
Address
12830 EL CAMINO REAL
SAN DIEGO, CA 92130
Phone: 858-558-2871
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
98
Momentum?
69
Short Sent.?
74
Piotroski F-Score?2/9Weak
Altman Z-Score?4.96Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?6.52%Elevated
Short Interest?8.3M
Days to Cover?5.9
Free Float127.6M
Avg Daily Volume1.4M
Settlement Date2026-10-30
Financial Health
Current Ratio?3.82Strong
Quick Ratio?3.70Strong
Cash Ratio?0.97Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
78/100
P/E?
Peers
100
S&P
97
9.0CHEAP▾
P/B?
Peers
100
S&P
67
2.34CHEAP▾
P/S?
Peers
100
S&P
55
2.70CHEAP▾
P/FCF?
Peers
100
S&P
17
39.5PRICEY▾
EV/EBITDA?
Peers
100
S&P
20
21.6HIGH▾
EV/Sales?
Peers
100
S&P
69
2.43CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
75
26.1%STRONG▾
ROA?
Peers
50
S&P
97
20.2%STRONG▾
Cash Flow & Enterprise
FCF?$82.0M
Enterprise Value?$2.9B
Fundamentals ratios updated end of day